1. Catalog
  2. 2025 Webinar - Mother to Child Transmission Hepati ...
2025 Webinar - Mother to Child Transmission Hepatitis B Webinar
Create Account
Availability
Registration Required
https://aasld.zoom.us/j/85104130965
Sep 16, 2025 12:00 PM - 1:00 PM ET
Cost
$0.00
Credit Offered
No Credit Offered
  • Description
  • Learning Objectives
  • Faculty
  • Recommended
Mother-to-child transmission (MTCT) remains the predominant form of virological spread of hepatitis B worldwide. Effective tools to mitigate MTCT exist, but are heterogeneously implemented. Innovations to the standard regimen have recently illustrated simplified approaches to MTCT prevention that could be more effectively adopted, particularly in resource-limited settings.

The webinar will provide a concise review of current standard of care, including an overview of AASLD guidelines. A high-yield discussion on the evolving literature of antiviral therapies utilized in pregnancy would also be included, including a synopsis on the recent clinical trial in JAMA demonstrating benefit with use of tenofovir disoproxil fumarate (TDF) in early pregnancy.
Upon completion of this activity, a learner should be able to:

• Identify the current standard of care to mitigate mother-to-child transmission (MTCT) of HBV
• Describe the standard of care to curtail MTCT?
• Define how and when the anti-viral therapy should be used and started in pregnancy
This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education. The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Peter Block, MD
Nothing to Disclose

Calvin Pan, MD
Grant/Research Support: Gilead, Wuxi Hisky Medical Technologies Co., Ltd

Robert Gish, MD
Scientific Consultant/Advisor: 
Intercept, Ipsen, Janssen, JBS Science, Kinnate Bio, Merck, Mirum, Precision BioSciences, Pfizer, Seres Therapeutics, Topography Health, Tune Therapeutics, Venatorx, Virion, Fibronostics, Fujifilm/Wako, Perspectum, Quest, Sonic Incytes, Abacus, Abbott, AbbVie, Albireo, Aligos, Altimunne, Antios, Arrowhead, AstraZeneca, Audentes Therapeutics, Corcept, Dynavax, Effectus, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, GlaxoSmithKline, Helios, HepaTX
Powered By